Avalo Therapeutics, Inc.

Name: Avalo Therapeutics, Inc. standardized financial statements, quarterly
Creator: Listed

AVTXNasdaqCIK 1534120HealthcareFiscal year ends Dec 31

Share this page

Link

Story card, 1080 × 1920

Standardized line items from XBRL company facts, the last twelve quarters. Negative values are in parentheses. A figure marked d is derived from year-to-date figures.

Income statement

Revenue$59.0k, Q4 FY2025

Operating income−$31.5m, Q2 FY2026

Net income−$36.4m, Q2 FY2026

Avalo Therapeutics, Inc., income statement, quarterly
Line item	Unit	Q3 FY20232023-09-30	Q4 FY20232023-12-31	Q1 FY20242024-03-31	Q2 FY20242024-06-30	Q3 FY20242024-09-30	Q4 FY20242024-12-31	Q1 FY20252025-03-31	Q2 FY20252025-06-30	Q3 FY20252025-09-30	Q4 FY20252025-12-31	Q1 FY20262026-03-31	Q2 FY20262026-06-30
Revenue	$m	0.2	0.6	0.0	0.0	0.2	0.2	not reported	not reported	0.0	0.1	not reported	not reported
Cost of revenue	$m	0.2	(0.2)	(0.1)	0.3	(0.7)	not reported	not reported	0.0	not reported	not reported	not reported	not reported
Research and development	$m	not reported	not reported	not reported	not reported	not reported	not reported	not reported	not reported	not reported	not reported	not reported	not reported
Selling, general and administrative	$m	2.5	2.7	not reported	not reported	not reported	not reported	not reported	not reported	not reported	not reported	not reported	not reported
Operating income	$m	(3.8)	(7.7)	(32.8)	(9.6)	(12.9)	(13.3)	(14.7)	(19.3)	(19.2)	(19.7)	(20.9)	(31.5)
Interest expense	$m	not reported	not reported	not reported	not reported	not reported	not reported	not reported	not reported	not reported	not reported	not reported	not reported
Income tax	$m	0.0	(0.0)	0.0	0.0	(0.0)	0.1	0.0	0.0	0.0	0.1	0.0	0.0
Net income	$m	(5.2)	(8.2)	(121)	98.5	23.0	(35.3)	(13.1)	(20.8)	(30.6)	(13.7)	(19.6)	(36.4)
Diluted EPS	$ per share	(26.83)	not reported	(141.14)	(14.07)	(2.83)	not reported	(1.25)	(1.92)	(2.19)	not reported	(0.98)	(0.83)
Basic EPS	$ per share	(26.83)	not reported	(141.14)	4.21	0.98	not reported	(1.25)	(1.92)	(2.19)	not reported	(0.98)	(0.83)

Balance sheet

Cash and equivalents$85.4m, Q2 FY2026

Shareholders' equity$448.7m, Q2 FY2026

Avalo Therapeutics, Inc., balance sheet, quarterly
Line item	Unit	Q3 FY20232023-09-30	FY20232023-12-31	Q1 FY20242024-03-31	Q2 FY20242024-06-30	Q3 FY20242024-09-30	FY20242024-12-31	Q1 FY20252025-03-31	Q2 FY20252025-06-30	Q3 FY20252025-09-30	FY20252025-12-31	Q1 FY20262026-03-31	Q2 FY20262026-06-30
Cash and equivalents	$m	10.2	7.4	110	93.4	81.9	135	125	42.3	27.0	15.9	25.0	85.4
Current assets	$m	12.7	8.4	111	95.9	86.1	139	127	115	114	105	88.8	408
Total assets	$m	29.3	21.0	124	108	98.5	151	139	127	125	116	99.9	491
Current liabilities	$m	6.0	4.6	216	96.4	60.7	7.0	5.6	9.3	8.0	12.9	11.6	21.1
Total liabilities	$m	14.6	13.7	225	110	75.7	17.7	15.9	22.0	33.6	33.4	31.6	42.1
Long-term debt	$m	not reported	not reported	not reported	not reported	not reported	not reported	not reported	not reported	not reported	not reported	not reported	not reported
Current portion of debt	$m	not reported	not reported	not reported	not reported	not reported	not reported	not reported	not reported	not reported	not reported	not reported	not reported
Shareholders' equity	$m	14.7	7.3	(113)	(13.6)	21.1	133	123	105	91.5	83.0	68.3	449

Cash flow

Operating cash flow−$20.0m, Q2 FY2026

Avalo Therapeutics, Inc., cash flow, quarterly
Line item	Unit	Q3 FY20232023-09-30	Q4 FY20232023-12-31	Q1 FY20242024-03-31	Q2 FY20242024-06-30	Q3 FY20242024-09-30	Q4 FY20242024-12-31	Q1 FY20252025-03-31	Q2 FY20252025-06-30	Q3 FY20252025-09-30	Q4 FY20252025-12-31	Q1 FY20262026-03-31	Q2 FY20262026-06-30
Operating cash flow	$m	(6.8)	(2.8)	(6.2)	(16.3)	(11.5)	(15.0)	(9.5)	(11.4)	(16.4)	(14.2)	(17.7)	(20.0)
Capital expenditure	$m	not reported	not reported	not reported	not reported	not reported	not reported	not reported	not reported	not reported	not reported	not reported	not reported

Diluted shares (weighted)43.60m, Q2 FY2026

Avalo Therapeutics, Inc., shares, quarterly
Line item	Unit	Q3 FY20222022-09-30	Q1 FY20232023-03-31	Q2 FY20232023-06-30	Q3 FY20232023-09-30	Q1 FY20242024-03-31	Q2 FY20242024-06-30	Q3 FY20242024-09-30	Q1 FY20252025-03-31	Q2 FY20252025-06-30	Q3 FY20252025-09-30	Q1 FY20262026-03-31	Q2 FY20262026-06-30
Diluted shares (weighted)	m shares	9.4	0.0	0.1	0.2	0.9	7.7	10.8	10.5	10.8	14.0	20.1	43.6

Shares outstanding: 53.63m at Aug 3, 2026, from the cover of the 10-Q filed Aug 6, 2026.

Source: SEC EDGAR, XBRL company facts. Last ingested by Listed: Oct 24, 2026, 15:42 ET. Listed shows no prices and gives no investment advice.